EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Fucosylation limits ADCC in clinically used anti‐ RhD monoclonal antibodies

Gabriela Koike iD, Albert Bondt iD, Douwe Schulte, Rien Leuvenink, Dirk Jan Mons, Peter C Ligthart, E Joanne T Verweij iD, AFRICARhE Consortium, Albert J R Heck, C Ellen van der Schoot, Gestur Vidarsson

Transfusion · 2026-11 · 66 (11) · 2360-2372

DOI: 10.1111/trf.18449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 13.10.2025. Verfasst von Gabriela Koike und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department Research, Immunoglobulin Research Laboratory, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibody-Dependent Cell Cytotoxicity, Fucose, Rho(D) Immune Globulin, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GV, Utrecht University, AJR Heck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Haemolytic disease of the fetus and newborn (HDFN) is caused by maternal alloantibodies, often targeting the D antigen on fetal red blood cells. Maternal immunization is preventable with timely administration of anti‐D polyclonal antibodies (pAbs). Although the mechanisms of action for pAbs are not completely known, clinical efficacy has been suggested to be associated with afucosylated anti‐D IgG and strong Fc‐receptor‐mediated antibody‐dependent cellular cytotoxicity (ADCC). Anti‐D pAbs are derived from hyperimmunized individuals, which makes the supply expensive and donor dependent. Monoclonal antibodies (mAbs) offer an alternative, but none have successfully prevented HDFN; some of them even enhanced alloimmunization. Despite lacking food and drug administration / European medicines agency (FDA/EMA) approval, two mAbs—Rhoclone™ and Trinbelimab (TBL) (Anti D®)—are widely used in low/middle‐income countries. Study Design and Methods Here we investigated functional and structural properties of these mAbs, including epitope mapping, glycan composition, and de novo sequencing by liquid chromatography tandem mass spectrometry (LC–MS/MS). Then, antibody engineering was employed to enhance ADCC potential.

Results

Both Rhoclone (Rho) and TBL recognized RhD‐epitope 5.5. Amino acid sequencing revealed these mAbs to be identical at the protein level, and that TBL had lower fucosylation (86%) than Rho (96%). Both mAbs had lower ADCC activity than anti‐D pAb Rhophylac®. ADCC performance was correlated with fucosylation levels: afucosylated engineered anti‐D > pAbs > TBL > Rho ≈ fucosylated anti‐D control. Glycoengineered versions with low fucose showed markedly enhanced natural killer cell (NK)‐cell‐mediated ADCC.

Discussion

Afucosylation of anti‐D monoclonals mimics polyclonal anti‐D and enhances their ADCC. Future efforts should focus on determining if these functional differences translate to clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibody-Dependent Cell CytotoxicityFucoseRho(D) Immune GlobulinAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansGlycosylationErythroblastosis, FetalFemaleEpitope Mapping

Stichwörter der Autor:innen

IgG glycosylationantibody de novo sequencingantibody‐dependent cytotoxicityanti‐RhD antibodieshaemolytic disease of the fetus and the newborn

Substanzen

FucoseRho(D) Immune GlobulinAntibodies, MonoclonalRHO(D) antibodyAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department Research, Immunoglobulin Research Laboratory, Amsterdam, The Netherlands.
  • Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Utrecht, The Netherlands.
  • Netherlands Proteomic Center, Utrecht, The Netherlands.
  • Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands.
  • Department of Obstetrics and Gynecology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Landsteiner Laboratory, Amsterdam University Medical Center, Amsterdam, The Netherlands.

ORCID-Profile: Gabriela Koike, Albert Bondt, E Joanne T Verweij

Förderung

  • GV
  • Utrecht University
  • AJR Heck
  • Genmab to A Bondt
  • Grand Valley State University
  • Universiteit Utrecht

Zitieren

APA

Koike, G., Bondt, A., Schulte, D., Leuvenink, R., Mons, D. J., Ligthart, P. C., Verweij, E. J. T., AFRICARhE Consortium, Heck, A. J. R., van der Schoot, C. E., & Vidarsson, G. (2026). Fucosylation limits ADCC in clinically used anti‐ RhD monoclonal antibodies. Transfusion, 66(11), 2360-2372. https://doi.org/10.1111/trf.18449

Vancouver

Koike G, Bondt A, Schulte D, Leuvenink R, Mons DJ, Ligthart PC, et al. Fucosylation limits ADCC in clinically used anti‐ RhD monoclonal antibodies. Transfusion. 2026;66(11):2360-2372. doi:10.1111/trf.18449

BibTeX
@article{Koike2026,
  author = {Koike, Gabriela and Bondt, Albert and Schulte, Douwe and Leuvenink, Rien and Mons, Dirk Jan and Ligthart, Peter C and Verweij, E Joanne T and AFRICARhE Consortium, AFRICARhE Consortium and Heck, Albert J R and van der Schoot, C Ellen and Vidarsson, Gestur},
  title = {Fucosylation limits ADCC in clinically used anti‐ RhD monoclonal antibodies},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {11},
  pages = {2360--2372},
  doi = {10.1111/trf.18449}
}
Kostenlos starten →